178 related articles for article (PubMed ID: 36879300)
1. Immunotherapy trials in Parkinson's disease: challenges.
Xiao B; Tan EK
J Transl Med; 2023 Mar; 21(1):178. PubMed ID: 36879300
[No Abstract] [Full Text] [Related]
2. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Parkinson's disease: Current status and future directions.
Chatterjee D; Kordower JH
Neurobiol Dis; 2019 Dec; 132():104587. PubMed ID: 31454546
[TBL] [Abstract][Full Text] [Related]
4. Immunologic treatment of Parkinson's disease.
Jankovic J
Immunotherapy; 2018 Feb; 10(2):81-84. PubMed ID: 29260621
[No Abstract] [Full Text] [Related]
5. [Disease-Modifying Therapy for Parkinson's Disease].
Shimura H; Hattori N
Brain Nerve; 2017 Feb; 69(2):159-165. PubMed ID: 28202824
[TBL] [Abstract][Full Text] [Related]
6. Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.
Zella MAS; Metzdorf J; Ostendorf F; Maass F; Muhlack S; Gold R; Haghikia A; Tönges L
Cells; 2019 Jan; 8(2):. PubMed ID: 30708997
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trial Highlights: Targetting Alpha-Synuclein.
McFarthing K; Simuni T
J Parkinsons Dis; 2019; 9(1):5-16. PubMed ID: 30741694
[No Abstract] [Full Text] [Related]
8. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
Wang Z; Gao G; Duan C; Yang H
Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
10. The safety and effectiveness of α-synuclein immunotherapy vs. placebo for the treatment of Parkinson's disease: a systematic review and meta-analysis.
Hu F; Zhang S; Wang C; Zhou H; Shi H
Ann Palliat Med; 2022 Dec; 11(12):3764-3774. PubMed ID: 36636001
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies for Parkinson's Disease: Progression of Clinical Development.
Teng JS; Ooi YY; Chye SM; Ling APK; Koh RY
CNS Neurol Disord Drug Targets; 2021; 20(9):802-813. PubMed ID: 34042040
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
Volc D; Poewe W; Kutzelnigg A; Lührs P; Thun-Hohenstein C; Schneeberger A; Galabova G; Majbour N; Vaikath N; El-Agnaf O; Winter D; Mihailovska E; Mairhofer A; Schwenke C; Staffler G; Medori R
Lancet Neurol; 2020 Jul; 19(7):591-600. PubMed ID: 32562684
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic approaches to target alpha-synuclein pathology.
Brundin P; Dave KD; Kordower JH
Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
[TBL] [Abstract][Full Text] [Related]
15. [Personalized treatment of Parkinson's disease].
Brockmann K; Gasser T
Nervenarzt; 2019 Aug; 90(8):767-772. PubMed ID: 31243506
[TBL] [Abstract][Full Text] [Related]
16. Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.
Henderson MX; Covell DJ; Chung CH; Pitkin RM; Sandler RM; Decker SC; Riddle DM; Zhang B; Gathagan RJ; James MJ; Trojanowski JQ; Brunden KR; Lee VMY; Luk KC
Neurobiol Dis; 2020 Mar; 136():104712. PubMed ID: 31837422
[TBL] [Abstract][Full Text] [Related]
17. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
[TBL] [Abstract][Full Text] [Related]
18. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
[TBL] [Abstract][Full Text] [Related]
19. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
20. Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials.
Antonini A; Bravi D; Sandre M; Bubacco L
Expert Opin Investig Drugs; 2020 Jul; 29(7):685-695. PubMed ID: 32419521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
